Basiliximab for GVHD- pro
Basiliximab (trade name Simulect) is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants.The α subunit (CD25) of interleukin-2 (IL-2) receptor is expressed predominantly in activated T lymphocytes. Basiliximab has shown promising results by achieving 71% of CR in the initial a phase I study published in 2002 with 17 patients29. Funke et al. published in 2005 their experience in 34 patients with refractory aGVHD grade III-IV, with approximately 80% of response and 30% overall five-year survival. Since then several other confirmatory studies have demonstrated significantefficacy.
Wang JZ et al, Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation.Transplant Proc. 2011 Jun;43(5):1928-33.
Mahmoudjafari, Zahra et al.Basiliximab for the Treatment of Steroid Refractory Acute Graft-Versus-Host-Disease Following Allogeneic Stem Cell Transplantation
Biology of Blood and Marrow Transplantation , Volume 22 , Issue 3 , S476 – S477